Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study
暂无分享,去创建一个
J. Routy | S. De Wit | Kimberly Smith | M. Aboud | B. Wynne | C. Wyen | A. Tenorio | F. Ajana | K. Pappa | F. Bisshop | O. Osiyemi | Ruolan Wang | M. Nascimento | M. Gartland | J. van Wyk | Jonathan Wright | J. Portilla Sogorb | M. Ait‐Khaled